Polypharmacy: An Overview
Polypharmacy is a growing public health problem which is affecting multitudes worldwide. This emerging public health problem is defined as the routine use of five or more medicines by an individual patient. Many researchers believe that the prevalence of polypharmacy is going to keep increasing since more people are being diagnosed with chronic diseases. Polypharmacy is known to cause many problems such as adverse drug reactions, drug to drug interactions, wastage of resources and increased treatment costs. Countries should raise awareness of polypharmacy and find solutions to this problem. Healthcare professionals should be educated on the dangers of polypharmacy, medication safety and polypharmacy management. Polypharmacy management means a whole systems approach which avoids the use of unnecessary medication for multimorbid patients while maximizing pharmaceutical care. There is ongoing research to investigate polypharmacy because very little is known in the existing literature. This article describes polypharmacy in detail, including the prevalence of polypharmacy, the economic impact of polypharmacy, medication safety and polypharmacy management. This article aims to give a much deeper insight into polypharmacy.
2. World Health Organization. Medication safety in polypharmacy: technical report. World Health Organization; 2019.
3. Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation. Making it safe and sound. London: The King’s Fund. 2013 Nov.
4. Davies EA, O'mahony MS. Adverse drug reactions in special populations–the elderly. Br J Clin Pharmacol.2015; 80(4): 796-807.
5. World Health Organization. Global health and ageing. Geneva: US: National Institute of Aging; 2011.
6. Organisation for Economic Co-operation and Development. Global Forum on Transparency and Exchange of Information for Tax Purposes Peer Reviews: Finland 2013: Combined: Phase 1+ Phase 2, Incorporating Phase 2 Ratings. OECD Publishing; 2013.
7. Ornstein SM, Nietert PJ, Jenkins RG, Litvin CB. The prevalence of chronic diseases and multimorbidity in primary care practice: a PPRNet report. The Journal of the American Board of Family Medicine. 2013; 26(5): 518-24.
8. Boyd CM, Fortin M. Future of multimorbidity research: how should understanding of multimorbidity inform health system design? Public Health Reviews. 2010;32(2):451-74.
9. Aitken, Murray and Gorokhovich, Lyudmila, Advancing the Responsible Use of Medicines: Applying Levers for Change (September 17, 2012). Available at SSRN: https://ssrn.com/abstract=2222541 or http://dx.doi.org/10.2139/ssrn.2222541
10. Gillespie U, Alassaad A, Henrohn D, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med. 2009 1; 169(9): 894-900.
11. Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaizier N, Waters H, Bates DW. The global burden of unsafe medical care: analytic modelling of observational studies. BMJ Qual Saf. 2013; 22(10): 809-15.
12. World Health Organization. Promoting rational use of medicines: core components. World Health Organization; 2002.
13. Beyene KA, Sheridan J, Aspden T. Prescription medication sharing: a systematic review of the literature. Am J Public Health. 2014; 104(4): e15-26.
14. World Health Organization. The importance of pharmacovigilance: Safety monitoring of medicinal products. Geneva: World Health Organization; 2002.
15. Royal S, Smeaton L, Avery AJ, Hurwitz B, Sheikh A. Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta-analysis. BMJ Qual Saf. 2006; 15(1): 23-31.
16. Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counselling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006;166(5): 565-71.
17. Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm.2013; 66(3): 201-2.
18. Aronson JK. Polypharmacy, appropriate and inappropriate. Br J Gen Pract. 2006;56(528):484-5.
|Issue||Vol 10, No 4 (Autumn 2022)|
|Polypharmacy Adverse Drug Reaction Drug-Drug Interaction|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|